PCL 016
(Synonyms: 2-吡啶甲酸) 目录号 : GC32372
Picolinic acid (PCL 016) is a pyridine carboxylate metabolite of tryptophan and acts as an anti-infective and immunomodulator. It acts by binding with the zinc associated with zinc finger proteins to alter their structure and inhibit function.
Cas No.:98-98-6
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Animal experiment: | Rabbits[1]25 NZW rabbits are topically inoculated in both eyes, following corneal scarification, with 1.5 x 106 pfu/eye of Ad5. On day 1, the rabbits are divided into 6 topical treatment groups: I - 1.5% PCL 016 pH 7.0 (n=4); II - 0.8% PCL 016 pH 7.0 (n=4); III - 0.369% PCL 016 pH 7.0 (n=4); IV - 0.369% PCL 016 pH 4.0 (n=4); V - 0.5% Cidofovir (CDV) (n=4); VI - Control (saline) (n=5). PCL 016 and control rabbits are treated in both eyes 4 times daily for 7 days, while CDV rabbits are treated in both eyes twice daily for 7 days. All eyes are cultured for virus on days 0, 1, 3, 4, 5, 7, 9, 11, and 14[1]. |
References: [1]. E.G. Romanowski, et al. A Novel Topical Antiviral Agent, PCL–016 (Picolinic Acid), Inhibits Adenovirus Replication in the Ad5/NZW Rabbit Ocular Model. ARVO Annual Meeting Abstract. May 2005 Volume 46, Issue 13. | |
Picolinic acid (PCL 016) is a pyridine carboxylate metabolite of tryptophan and acts as an anti-infective and immunomodulator. It acts by binding with the zinc associated with zinc finger proteins to alter their structure and inhibit function.
| Cas No. | 98-98-6 | SDF | |
| 别名 | 2-吡啶甲酸 | ||
| Canonical SMILES | O=C(O)C1=CC=CC=N1 | ||
| 分子式 | C6H5NO2 | 分子量 | 123.11 |
| 溶解度 | DMSO : ≥ 100 mg/mL (812.28 mM);Water : ≥ 50 mg/mL (406.14 mM) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 8.1228 mL | 40.6141 mL | 81.2282 mL |
| 5 mM | 1.6246 mL | 8.1228 mL | 16.2456 mL |
| 10 mM | 0.8123 mL | 4.0614 mL | 8.1228 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。